Anumana, Inc. - Company Market Research Report

Company Overview

• Name: Anumana, Inc.

• Mission: Anumana is dedicated to harnessing the electrical signals of the heart to diagnose and intervene in cardiac care earlier and more effectively through AI technology.

• Founded: No information is available.

• Founders: No information is available.

• Key People:

• Murali Aravamudan, Executive Chairman of the Board

• Maulik Nanavaty, Chief Executive Officer

• David McMullin, Chief Business Officer

• Harry S. Palmin, Chief Financial Officer

• Kyle Bettigole, SVP, General Counsel

• Animesh Agarwal, Vice President of Product

• Samir Awasthi, MD, PhD, Vice President of Clinical Research

• Rakesh Barve, PhD, SVP of Data Science and Engineering

• Suzanne Goodman, Vice President of Regulatory & Quality

• Tyler Wagner, PhD, Vice President of Biomedical Research

• Advisors:

• Paul Friedman, MD from Mayo Clinic

• Samuel J. Asirvatham, MD from Mayo Clinic

• Zachi Attia, PhD from Mayo Clinic

• Francisco Lopez-Jiminez, MD, MBA from Mayo Clinic

• Rickey Carter, PhD from Mayo Clinic

• Additional esteemed professionals from other notable institutions.

• Headquarters: Cambridge, Massachusetts

• Number of Employees: No information is available.

• Revenue: No information is available.

• What the Company is Known For: Anumana is recognized for its AI-driven technology solutions that improve cardiovascular care by offering early diagnoses and intervention capabilities.

Products

AI Medical Solutions

• ECG-AI Platform:

• High-Level Description: Uses advanced AI to analyze ECG data for early detection of cardiovascular diseases.

• Key Features:

• Algorithms trained on extensive ECG datasets.

• FDA-cleared ECG-AI LEF for detecting low ejection fraction.

Electrocardiograhic and Electrophysiology Pipelines

• Electrocardiography Pipeline:

• Includes algorithms for detection of diseases such as pulmonary hypertension, cardiac amyloidosis, and hyperkalemia, some of which have received FDA Breakthrough Device Designation.

• Electrophysiology Pipeline:

• Targets improving procedure accuracy, safety, and outcomes in cardiac electrophysiology.

Software Solutions

• Innovative Clinical Software:

• Integrates AI solutions with existing clinical workflows, improving decision-making and patient care.

• Integration Tools:

• Designed to work with Electronic Health Records (EHR) and other point-of-care systems.

Recent Developments

• New Products & Features:

• Anumana's ECG-AI LEF received FDA clearance in 2023 for detecting low ejection fraction.

• New AI algorithms for pulmonary hypertension and cardiac amyloidosis have received FDA Breakthrough Device Designation.

• Partnerships:

• Collaboration with InfoBionic.Ai to advance remote cardiac monitoring technologies.

• Strategic alliance with Novartis to develop AI-driven diagnostic tools for heart diseases.

• Awards:

• The ECG-AI platform won the 2024 MedTech Breakthrough Award for best new technology in cardiology.

Conclusion

Anumana, Inc. is a leading AI health technology company focused on revolutionizing cardiac care through innovative AI solutions and strategic partnerships. By developing a robust portfolio of AI algorithms and tools, Anumana aims to transform the way cardiac diseases are detected and managed, providing critical benefits to patient outcomes and healthcare efficiency.